Article

Cardiovascular changes in renal failure.

Department of Pathology, University of Erlangen, Germany.
Blood Purification (Impact Factor: 1.92). 02/2002; 20(5):462-5. DOI: 10.1159/000063551
Source: PubMed

ABSTRACT In patients with renal failure cardiovascular complications are an important clinical problem and cardiac death is the main cause of death in these patients. It is well documented that cardiac risk is increased by a factor of 20 in uremic patients compared with age- and sex-matched segments of the general population. This finding in patients with renal failure can be at least partially explained by the well-described structural and metabolic abnormalities of the myocardium. The present article focuses on the structural changes in the heart and the vasculature and their potential repercussions for cardiovascular function, in particular their contribution to the high cardiovascular morbidity and mortality in patients with renal failure.

0 Followers
 · 
76 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular calcification is both a risk factor and contributor to morbidity and mortality. Patients with chronic kidney disease (and/or diabetes) exhibit accelerated calcification of the intima, media, heart valves and likely the myocardium as well as the rare condition of calcific uraemic arteriolopathy (calciphylaxis). Pathomechanistically, an imbalance of promoters (e.g. calcium and phosphate) and inhibitors (e.g. fetuin-A and matrix Gla protein) is central in the development of calcification. Next to biochemical and proteinacous alterations, cellular processes are also involved in the pathogenesis. Vascular smooth muscle cells undergo osteochondrogenesis, excrete vesicles and show signs of senescence. Therapeutically, measures to prevent the initiation of calcification by correcting the imbalance of promoters and inhibitors appear to be essential. In contrast to prevention, therapeutic regression of cardiovascular calcification in humans has been rarely reported. Measures to enhance secondary prevention in patients with established cardiovascular calcifications are currently being tested in clinical trials. © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
    Nephrology Dialysis Transplantation 04/2015; DOI:10.1093/ndt/gfv111 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper is the third in a series of reviews published in this issue resulting from the University of California Davis Cardiovascular Symposium 2014: Systems approach to understanding cardiac excitation–contraction coupling and arrhythmias: Na+ channel and Na+ transport. The goal of the symposium was to bring together experts in the field to discuss points of consensus and controversy on the topic of sodium in the heart. The present review focuses on cardiac Na+/Ca2+ exchange (NCX) and Na+/K+-ATPase (NKA). While the relevance of Ca2+ homeostasis in cardiac function has been extensively investigated, the role of Na+ regulation in shaping heart function is often overlooked. Small changes in the cytoplasmic Na+ content have multiple effects on the heart by influencing intracellular Ca2+ and pH levels thereby modulating heart contractility. Therefore it is essential for heart cells to maintain Na+ homeostasis. Among the proteins that accomplish this task are the Na+/Ca2+ exchanger (NCX) and the Na+/K+ pump (NKA). By transporting three Na+ ions into the cytoplasm in exchange for one Ca2+ moved out, NCX is one of the main Na+ influx mechanisms in cardiomyocytes. Acting in the opposite direction, NKA moves Na+ ions from the cytoplasm to the extracellular space against their gradient by utilizing the energy released from ATP hydrolysis. A fine balance between these two processes controls the net amount of intracellular Na+ and aberrations in either of these two systems can have a large impact on cardiac contractility. Due to the relevant role of these two proteins in Na+ homeostasis, the emphasis of this review is on recent developments regarding the cardiac Na+/Ca2+ exchanger (NCX1) and Na+/K+ pump and the controversies that still persist in the field.
    The Journal of Physiology 03/2015; 593(6). DOI:10.1113/jphysiol.2014.282319 · 4.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introducción No ha sido bien consensuada una definición apropiada del síndrome cardiorrenal (SCR). Actualmente, se acepta que sería la presencia de falla cardíaca y renal concomitante, con sobrecarga de volumen y resistencia a las diferentes te-rapias estándares para esta patología, con mayor exacerba-ción de los síntomas. En pacientes con insuficiencia cardíaca (IC), ya sea con fun-ción sistólica ventricular izquierda (FSVI) deprimida o no, el tratamiento de la misma, puede provocar deterioro de la función renal (FR), complicando el tratamiento aún más de la IC y empeorando el pronóstico. La insuficiencia renal (IR), en los pacientes portadores de esta entidad, se ha convertido en un reconocido factor de riesgo independiente para morbimortalidad 1,2 . Sin embargo, la magnitud precisa de este riesgo no es aún muy clara, sal-vo algunos datos presentados en las Guías de Práctica Clí-nica para la Enfermedad Renal Crónica 3 donde analizaron eventos cardiovasculares (CV) en una población de 1.120.295 personas de un sistema integrado de un seguro de Salud, quienes establecieron el riesgo de muerte y even-tos CV en personas con filtrado glomerular (FG) menor de 60 ml/minuto (la tasa de mortalidad para un clearance entre 45 a 59 ml/minuto fue del 17% y para filtrados menores de 15ml/minuto fue de 600%; la tasa de eventos CV para el grupo de 45-59 ml/minuto fue de 43% y en el de menos de 15 ml/minuto del 343%). De este trabajo no se puede extrapolar pacientes con IC pura, ya que se trata de una población donde están incluidos todo tipo de eventos CV. Sí está claro, que tanto la IC como la enfermedad renal, pueden tener un común estado original de enfermedad, ejem-plo: diabetes, hipertensión arterial (HTA), tabaquismo, dis-lipidemia, aterosclerosis, edad avanzada, que ocasionarían igual daño macro y microvascular en ambos órganos y que comparten mecanismos fisiopatológicos semejantes siendo algunos de ellos, igualmente deletéreos. En la mayoría de los estudios clínicos, los pacientes con SCR, fueron sistemáticamente excluidos de los mismos (creatinininemia > 2,3 mg%), motivo por el cual, la farma-coterapia óptima en estos pacientes permanece pobremente definida, especialmente en la IR severa 4 . El propósito de este análisis, es actualizar los datos obteni-dos hasta la fecha sobre la prevalencia, fisiopatología, fac-tores de riesgo del SCR.
    09/2006; 1(3):131-135.